Cellectis (CLLS)

• Market cap: $391M
• 1 day: 9.24%
• 5 days: 8.64%
• 1 month: -6.47%
• 3 months: 36.36%
• 6 months: 182.61%
• Year to date: 115.47%
• 1 year: 104.19%
• 5 years: -80.56%
• 10 years: -88.71%
• Sector: Healthcare
• Industry: Biotechnology

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Employees: 222